Canaccord analyst Whitney Ijem lowered the firm’s price target on Rocket Pharmaceuticals to $49 from $50 and keeps a Buy rating on the shares. The firm said the 4Q earnings report was uneventful with pipeline updates largely on track.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on RCKT:
